Clinical trials
Phase 3 Epilepsy trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
69 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 9 |
| 2010 | 5 |
| 2011 | 8 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Terminated | 10 |
| Recruiting | 4 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UCB Pharma | 11 |
| GlaxoSmithKline | 6 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 5 |
| UCB Pharma SA | 5 |
| UCB BIOSCIENCES, Inc. | 4 |
| UCB Biopharma S.P.R.L. | 4 |
| Xenon Pharmaceuticals Inc. | 4 |
| Bial - Portela C S.A. | 3 |
| Eisai Inc. | 3 |
| Longboard Pharmaceuticals | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Epilepsy | 69 |
| Seizures | 25 |
| Epilepsies, Partial | 11 |
| Epilepsies, Myoclonic | 5 |
| Brain Diseases | 3 |
| Neurodevelopmental Disorders | 3 |
| Epilepsy, Tonic-Clonic | 2 |
| Lennox Gastaut Syndrome | 2 |
| Drug Resistant Epilepsy | 1 |
| Epilepsy, Complex Partial | 1 |
Trials
Showing 1 to 25 of 69. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.